Literature DB >> 15815016

Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis.

D Genovese1, S Dettori, C Argentini, U Villano, P Chionne, M Angelico, M Rapicetta.   

Abstract

We analyzed hepatitis C virus (HCV) genotype 4 isolates circulating in the Alexandria District (Egypt) in terms of genetic divergence and the presence of different subtypes. Hypervariable region 1 (HVR1) and the NH2 region of the E2 protein were characterized, and the heterogeneity of subtype 4a isolates was evaluated by analyzing epitope frequencies, immunoproteasome prediction, and possible glycosylation patterns. The heterogeneity of the nucleotide sequences was greater than that found in previous studies, which reported only subtype 4a. Subtype 4a was most common (78% of cases), yet four new subtypes were found, with subtype 4m representing 11% of the cases and the other three subtypes representing another 11%. Substantial heterogeneity was also found when the intrasubtype 4a sequences were analyzed. Differences in the probability of glycosylation and in the positions of the different sites were also observed. The analysis of the predicted cytotoxic-T-lymphocyte epitopes showed differences in both the potential proteosome cleavage and the prediction score. The Egyptian isolates in our study also showed high variability in terms of the HVR1 neutralization epitope. Five of these isolates showed amino acid substitutions never previously observed (a total of six positions). Four of these residues (in four different isolates) were in positions involved in anchoring to the E2 glycoprotein core and in maintaining the HVR1 conformation. The results of this study indicate that HCV genotype 4 in Egypt is extremely variable, not only in terms of sequence, but also in terms of functional and immunological determinants. These data should be taken into account in planning the development of vaccine trials in Egypt.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15815016      PMCID: PMC1081338          DOI: 10.1128/JCM.43.4.1902-1909.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  53 in total

1.  Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

Authors:  K Mori; Y Yasutomi; S Ohgimoto; T Nakasone; S Takamura; T Shioda; Y Nagai
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  MEGA2: molecular evolutionary genetics analysis software.

Authors:  S Kumar; K Tamura; I B Jakobsen; M Nei
Journal:  Bioinformatics       Date:  2001-12       Impact factor: 6.937

4.  Molecular characterisation of HCV genotype 4 isolates circulating in Italy.

Authors:  C Argentini; S Dettori; U Villano; V Guadagnino; D Infantolino; P Dentico; R C Coppola; M Rapicetta
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

5.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  The flexibility of the TCR allows recognition of a large set of naturally occurring epitope variants by HIV-specific cytotoxic T lymphocytes.

Authors:  F Buseyne; Y Rivière
Journal:  Int Immunol       Date:  2001-07       Impact factor: 4.823

7.  Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Authors:  A Fournillier; C Wychowski; D Boucreux; T F Baumert; J C Meunier; D Jacobs; S Muguet; E Depla; G Inchauspé
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions.

Authors:  B N Sobolev; V V Poroikov; L V Olenina; E F Kolesanova; A I Archakov
Journal:  J Viral Hepat       Date:  2000-09       Impact factor: 3.728

9.  Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.

Authors:  Nicole Frahm; B T Korber; C M Adams; J J Szinger; R Draenert; M M Addo; M E Feeney; K Yusim; K Sango; N V Brown; D SenGupta; A Piechocka-Trocha; T Simonis; F M Marincola; A G Wurcel; D R Stone; C J Russell; P Adolf; D Cohen; T Roach; A StJohn; A Khatri; K Davis; J Mullins; P J R Goulder; B D Walker; C Brander
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.

Authors:  Tiffany Slater-Handshy; Deborah A Droll; Xiaofeng Fan; Adrian M Di Bisceglie; Thomas J Chambers
Journal:  Virology       Date:  2004-02-05       Impact factor: 3.616

View more
  20 in total

1.  Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Authors:  O Anagnostou; S Manolakopoulos; G Bakoyannis; G Papatheodoridis; A Zisouli; M Raptopoulou-Gigi; E Manesis; I Ketikoglou; G Dalekos; C Gogos; T Vassiliadis; D Tzourmakliotis; S Karatapanis; S Kanatakis; - Zoumpoulis; A Hounta; S Koutsounas; G Giannoulis; N Tassopoulos; G Touloumi
Journal:  Hippokratia       Date:  2014-01       Impact factor: 0.471

2.  Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center.

Authors:  L A Kondili; D Genovese; C Argentini; P Chionne; P Toscani; R Fabro; R Cocconi; M Rapicetta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

3.  Hepatocellular carcinoma in Hepatitis C genotype 4 after viral clearance and in absence of cirrhosis: two case reports.

Authors:  Moutaz Derbala; Aliaa Amer
Journal:  Cases J       Date:  2009-09-15

4.  Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients.

Authors:  Hana A Elasifer; Yossif M Agnnyia; Basher A Al-Alagi; Mohamed A Daw
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

5.  Complete genomic sequences for hepatitis C virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t.

Authors:  Chunhua Li; Ling Lu; Xianghong Wu; Chuanxi Wang; Phil Bennett; Teng Lu; Donald Murphy
Journal:  J Gen Virol       Date:  2009-04-08       Impact factor: 3.891

6.  Subgenotyping and genetic variability of hepatitis C virus in Palestine.

Authors:  Sahar Rayan Da'as; Maysa Azzeh
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240

7.  Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.

Authors:  Barbara Ridolfi; Domenico Genovese; Claudio Argentini; Maria Teresa Maggiorella; Leonardo Sernicola; Stefano Buttò; Fausto Titti; Alessandra Borsetti; Barbara Ensoli
Journal:  Virus Genes       Date:  2007-11-30       Impact factor: 2.332

8.  Heterogeneity and new epitopes of hepatitis C virus genotype 4.

Authors:  Moataza H Omran; Wael Nabil; Samar S Youssef; Mervat El-Sayed; Mostafa K El Awady
Journal:  Hepat Mon       Date:  2013-08-01       Impact factor: 0.660

9.  Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.

Authors:  Abdo A Elfiky; Wael M Elshemey; Wissam A Gawad; Omar S Desoky
Journal:  Protein J       Date:  2013-01       Impact factor: 2.371

10.  Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients.

Authors:  Fatma Houissa Kchouk; Yousr Gorgi; Lamjed Bouslama; Imen Sfar; Rym Ayari; Hacene Khiri; Phillipe Halfon; Houda Aouadi; Saloua Jendoubi Ayed; Khaled Ayed; Taieb Ben Abdallah
Journal:  Viral Immunol       Date:  2013-02-01       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.